Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dupont Merck Reluma Tc-99m can help detect malignancies in both fatty and dense breasts, study shows.

This article was originally published in The Gray Sheet

Executive Summary

DUPONT MERCK RELUMA Tc-99m MARKER 70% ACCURATE IN DETECTING MALIGNANCY in a study group of women with nonpalpable suspected breast cancer found by mammography, Janet Baum, MD, Beth Israel Deaconess Medical Center, Boston, reported Dec. 2 at the Radiological Society of North America's annual meeting in Chicago. In the patient group, the test had an 82% negative predictive value. For breast masses detected through palpation, Tc-99m sestamibi, which Dupont Merck plans to market under the name Reluma, correctly identified 77% of the malignancies and had an 86% negative predictive value. All diagnoses were confirmed through excisional biopsy or mastectomy.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel